The Science Behind Our Technology:
In this webinar, Dr. Robert Anderson will share his perspective and experience on the adoption of umbilical cord allografts in sports-related foot and ankle surgical procedures.
Amniox Medical is supported by more than 30 years of research in characterizing and preserving the biology and functionality of human placental tissue. Our proprietary flagship CRYOTEK® process utilizes deep freezing to preserve the functional and structural integrity of the tissues while maintaining their natural hydrated state.
Regenerative healing that enhances the body’s recover from the injury or disease, has been pursued as far back as the early 20th century.1 In the decades since, it has come to be understood that the human fetus is capable of regenerative and scarless healing, and is the model that all regenerative therapies aspire to duplicate. Our research suggests that unique complex (HC-HA/PTX3) is a key factor in the regenerative qualities found in these tissues and drives an elegant orchestration of cytokines, growth factors to arrive at an advanced healing state. 4,5 Specifically, the fetus’ superior management of the body’s inflammatory mechanisms leads to organized and efficient tissue repair. Read More
If processed appropriately, fetal birth tissue retains these properties and effectively applies them to unrelated hosts through allografts, or human-to-human tissue transfers. 6,7,8 Our research suggests that this transplantation of biology into mature tissue provides a means of disrupting the inflammatory and scarring type of repair inherent to adult tissue, and drives a regenerative process of restorative repair (Cref). Amniox Medical’s patented flagship CRYOTEK® process utilizes freezing to preserve the functional and structural integrity of the tissues while maintaining their natural hydrated state. Other forms of processing that require dehydration of the matrix have been shown to degrade the critical biological, and may limit the tissue’s capabilities.
The clinical success of the CRYOTEK process has been demonstrated in more than 300 peer-reviewed publications and 300,000 human transplants. By devitalizing the resident living cells CRYOTEK reduces the risk of an immune reaction and preserves the functional components of the extracellular matrix. Read More
Amniox procures all tissue through elective donation within the United States. Donor eligibility requires a live mother to have given full consent and to have delivered a live birth via elective Cesarean section. Donor suitability is determined through physical and medical screening. This process is intended to ensure that each product is safe for transplantation.